SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate GEP-44, to be conducted with LabCorp. The studies are designed to assess safety, dosing parameters, and biomarkers across multiple species, supporting future Phase I clinical trials for the GLP-1 agonist peptide targeting Type II diabetes and obesity.
This advancement marks a significant step for SureNano as it transitions from a surfactant distribution company into a pharmaceutical-focused entity. The company has acquired GlucaPharm Inc., which developed GEP-44, a patented peptide aimed at addressing obesity and metabolic disorders with improved tolerability and potential non-injectable delivery, as referenced in a press release dated February 23, 2026. The IND-enabling studies are critical for determining the safety profile and dosing requirements before human trials can commence.
In parallel, SureNano outlined expanded investor outreach initiatives, including a strategic agreement with Investor Brand Network (IBN) to leverage its syndication network of more than 5,000 media outlets. The company also noted additional marketing engagements and early-stage discussions to potentially acquire or license intellectual property related to ibogaine-based therapies. These efforts are intended to strengthen market awareness while supporting continued advancement of its therapeutic pipeline.
The potential impact of GEP-44 could be substantial given the global prevalence of obesity and Type II diabetes. If successful, the candidate may offer an alternative to existing GLP-1 therapies with improved tolerability and a non-injectable delivery option, which could increase patient compliance. For investors and industry leaders, the progress toward clinical trials represents a key milestone in SureNano's pipeline valuation.
SureNano Science Ltd. is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical and biotechnology assets. The initial business involves the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound for nanoemulsions, under exclusive licenses in Canada, Oklahoma, and Colorado. The company is now evolving into a pharmaceutical-focused organization through the advancement of GEP-44.
For more information on the press release, visit https://ibn.fm/a6nGj. The latest news and updates relating to SURNF are available in the company's newsroom at https://ibn.fm/SURNF.
